Research programme: diabetes/obesity therapies - ChemGenex Pharmaceuticals/Merck-Sante

Drug Profile

Research programme: diabetes/obesity therapies - ChemGenex Pharmaceuticals/Merck-Sante

Alternative Names: CXS-102 SelS; CXS-121 SGIP1; CXS-203 PSARL

Latest Information Update: 30 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemGenex Pharmaceuticals; Merck Sante
  • Class
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 30 Oct 2008 Discontinued - Preclinical for Obesity in Australia (unspecified route)
  • 30 Oct 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in Australia (unspecified route)
  • 20 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top